Get the Stockscreener App
29.25
0.95%
-0.2463
Enliven Therapeutics Inc stock is traded at $29.25, with a volume of 212.93K.
It is down -0.95% in the last 24 hours and up +5.87% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$29.50
Open:
$28.67
24h Volume:
212.93K
Relative Volume:
0.22
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-97.21M
P/E Ratio:
-15.85
EPS:
-1.8459
Net Cash Flow:
$-71.82M
1W Performance:
+3.18%
1M Performance:
+5.87%
6M Performance:
+39.47%
1Y Performance:
+48.93%
1-Day Range:
$28.01
$29.45
1-Week Range:
$27.98
$30.04
52-Week Range:
$13.30
$30.22
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
29.25 | 1.75B | 0 | -97.21M | -71.82M | -1.8459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.81 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.54 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
753.52 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.21 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Biotech fireside chat: Enliven Therapeutics at TD Cowen event - Stock Titan
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Gains Report: Is First Internet Bancorp showing insider buyingJuly 2025 Action & High Conviction Investment Ideas - baoquankhu1.vn
Stock Market Recap: How sensitive is Enliven Therapeutics Inc to inflationJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January - MarketBeat
Can Enliven Therapeutics Inc disrupt its industryQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Richard Heyman plans Enliven (NASDAQ: ELVN) Rule 144 stock sale - Stock Titan
Will Enliven Therapeutics Inc. benefit from rising consumer demandJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What drives Enliven Therapeutics Inc.’s stock priceJuly 2025 Breakouts & Growth Focused Stock Reports - mfd.ru
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock - MarketBeat
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com UK
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares - Investing.com
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Bear Alert: Will AdvanSix Inc stock hit new highs in YEARQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Executive Sells 20,000 Shares - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside - DirectorsTalk Interviews
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aug Sectors: What is DATSs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Market Outlook: Is Enliven Therapeutics Inc attractive for institutional investorsStop Loss & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com South Africa
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):